Baricitinib for lung injury after sudden brain bleed
Treatments studied
Part of Brain & nervous system, Heart & circulation, Infections, Lungs & breathing clinical trials.
This study tests whether a medication called baricitinib can help protect the lungs in people who have had a sudden bleed around the brain. Baricitinib works by calming inflammation, which might reduce lung injury after the bleeding.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have a bleeding around the brain (subarachnoid hemorrhage) that started on its own.
- Your bleeding is rated as moderate to severe (Hunt-Hess score 3 or 4).
- You arrived at the hospital within 24 hours of the bleeding starting.
- You do not have a history of chronic lung disease, autoimmune disease, or a weak immune system.
- You are not pregnant or breastfeeding, and you are not taking other immune-suppressing drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a pill called baricitinib to see if it helps people recover from lung injury after a brain bleed. It is for patients who need a breathing machine due to ARDS that started within a week of the bleed.
This trial tests if baricitinib, an anti-inflammatory drug, can help people with bleeding in the brain from a head injury. It is for adults with moderate to severe traumatic brain injury who are not immediately having surgery.
This study tests whether the drug baricitinib, given after a mechanical clot-removal procedure, helps improve recovery in people who had a stroke from a large clot in the front of the brain. The drug may reduce inflammation and protect brain tissue.
This trial looks at how a severe brain bleed (subarachnoid hemorrhage) might affect lung function and hyaluronic acid buildup in the lungs. It aims to find better ways to protect breathing for patients in the intensive care unit.
This trial tests if baricitinib, a medication for rheumatoid arthritis, can improve blood clotting issues that some patients with active RA face. It is for adults whose RA is not well-controlled by standard treatments.
This study looks at how inflammation and changes in the blood-brain barrier occur after a spontaneous brain bleed. Researchers use special brain imaging and scans to understand these processes, which may help improve treatment in the future.
Hear when a new Spontaneous Subarachnoid Hemorrhage trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.